Survival proportions in SCID mice bearing disseminated MC/CAR MM cells. mAb hLL1 was administered to MC/CAR-bearing SCID mice at 4 dose schedules. Survival was compared with untreated MC/CAR-bearing SCID mice. ▵, 350 μg administered 5 days after tumor cells were grafted; ○, 350 μg/injection once a week for 2 weeks, treatment initiated 5 days after tumor cells were injected; ▴, 100 μg/injection 5 times/wk for 2 weeks, then twice weekly, treatment initiated 5 days after tumor cells were inoculated; □, 100 μg/injection 5 times/wk for 2 weeks, then twice weekly, treatment initiated 1 day after tumor cells were injected; and •, untreated control.